These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16886576)

  • 21. Etiology of Crohn's disease: Do certain food additives cause intestinal inflammation by molecular mimicry of mycobacterial lipids?
    Traunmüller F
    Med Hypotheses; 2005; 65(5):859-64. PubMed ID: 16043304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars.
    Borody TJ; Bilkey S; Wettstein AR; Leis S; Pang G; Tye S
    Dig Liver Dis; 2007 May; 39(5):438-44. PubMed ID: 17369114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paediatric inflammatory bowel disease in New Zealand.
    Yap J; Wesley A; Mouat S; Chin S
    N Z Med J; 2008 Oct; 121(1283):19-34. PubMed ID: 18841182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease.
    Eivindson M; Grønbaek H; Skogstrand K; Thorsen P; Frystyk J; Flyvbjerg A; Dahlerup JF
    Scand J Gastroenterol; 2007 Apr; 42(4):464-70. PubMed ID: 17454856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormalities in the upper gastrointestinal tract in inflammatory bowel disease.
    Ando T; Nobata K; Watanabe O; Kusugami K; Maeda O; Ishiguro K; Ohmiya N; Niwa Y; Goto H
    Inflammopharmacology; 2007 Jun; 15(3):101-4. PubMed ID: 17464554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
    Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
    Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Top-down versus Step-Up: new strategies in the treatment of Crohn's disease].
    Meier J; Sturm A
    Z Gastroenterol; 2009 Feb; 47(2):240-2. PubMed ID: 19197829
    [No Abstract]   [Full Text] [Related]  

  • 29. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
    Wehkamp J; Stange EF
    Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging therapeutic targets and strategies in Crohn's disease.
    Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease.
    Chrissafidou A; Malek M; Musch E
    Z Gastroenterol; 2007 Jul; 45(7):605-8. PubMed ID: 17620224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab in fistulizing Crohn's disease.
    Osterman MT; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):795-820. PubMed ID: 17129814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical perspectives in Crohn's disease. Moving forward with anti-TNF-alpha therapy: current needs and future treatments.
    Sandborn WJ
    Rev Gastroenterol Disord; 2007; 7 Suppl 2():S23-35. PubMed ID: 17392636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
    Späh F
    Br J Dermatol; 2008 Aug; 159 Suppl 2():10-7. PubMed ID: 18700910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of an elemental diet in Crohn's disease.
    Takahashi H; Ando T; Watanabe O; Maeda O; Ishiguro K; Ohmiya N; Niwa Y; Goto H
    Inflammopharmacology; 2007 Feb; 15(1):15-7. PubMed ID: 17323189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand.
    Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV
    Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hen egg lysozyme attenuates inflammation and modulates local gene expression in a porcine model of dextran sodium sulfate (DSS)-induced colitis.
    Lee M; Kovacs-Nolan J; Yang C; Archbold T; Fan MZ; Mine Y
    J Agric Food Chem; 2009 Mar; 57(6):2233-40. PubMed ID: 19231858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infliximab use in luminal Crohn's disease.
    Richter JA; Bickston SJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Certain immune-genes may affect Crohn disease. Advances in diagnosis, pathogenesis and treatment].
    Befrits R; Hultcrantz R
    Lakartidningen; 1998 Feb; 95(7):622-7. PubMed ID: 9495065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Th1 immune pathway as a therapeutic target in Crohn's disease.
    Bamias G; Sugawara K; Pagnini C; Cominelli F
    Curr Opin Investig Drugs; 2003 Nov; 4(11):1279-86. PubMed ID: 14758766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.